{"schema_version":"secwatch.filing_event.v1","accession":"0001656472-22-000111","form_type":"8-K","ticker":"CRON","cik":"0001656472","company_name":"Cronos Group Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.557369+00:00","generated_at":"2026-06-24T02:06:23.638846+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cronos Q2 net revenue $23.1M (+48% YoY); net loss narrows to $20.3M from $179.4M","bullets":["Consolidated net revenue $23.1M, up 48% YoY; Rest of World segment $21.6M (+61%); U.S. $1.5M (-34%).","Net loss $20.3M improved from $179.4M; Adjusted EBITDA -$18.8M vs -$49.8M a year earlier.","Gross profit $4.1M (gross margin 18%) vs -$15.8M (-101%) in Q2 2021; no inventory write-downs this quarter.","Realignment costs now expected at ~$6.4M (up from $5.8M); phased exit of U.S. wholesale beauty channel.","Arye Weigensberg appointed SVP Head of R&D; THCV productivity milestone achieved under Ginkgo partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001656472-22-000111","json":"https://secwatch.observer/filing/0001656472-22-000111.json","markdown":"https://secwatch.observer/filing/0001656472-22-000111.md","text":"https://secwatch.observer/filing/0001656472-22-000111.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1656472/000165647222000111/0001656472-22-000111-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1656472/000165647222000111/cron-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:06:23.638846+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}